Global Scans · Pharmaceuticals · Weekly Summary

• [New] Peptide-drug conjugates are especially notable, combining selective receptor binding with targeted delivery, and one analysis projects roughly 20% annual growth through 2035. Doctor NHS
• [New] China is projected to exhibit rapid volume growth driven by expanding centralized drug procurement programs and heavy state investments in urban hospital infrastructure. Persistence Market Research
• [New] Researchers from the Technion - Israel Institute of Technology and Tel Aviv University have developed an artificial intelligence system that could significantly speed the process of understanding proteins, a breakthrough with potential applications in drug discovery, biotechnology, and agriculture. Tel Aviv Diary
• [New] Donald Trump has repeatedly threatened to launch a ground invasion in Mexico to attack the drug cartels, ratcheting up fears for Mexican sovereignty. The Guardian
• [New] CIA and DEA operations in Mexican territory, along with accusations against Mexican politicians accused of links to drug trafficking, will be intensified as a form of more direct intervention in national politics. Mexico Solidarity Media
• [New] A most-favored-nation pricing framework, which would peg US drug prices to lower international levels, poses a direct threat to Novo's US pricing power, where it generates a large portion of its revenue. investing.com
• [New] Eliminating the clinical equivalence study requirement for interchangeability could materially increase expected net present value in large biosimilar markets. DrugPatentWatch - Transform Data into Market Domination
• [New] Biosimilar adoption in the United States is increasing as more biologic drugs face patent expirations, creating significant opportunities for developers despite concerns about a future shortage of biosimilar candidates. The Real Economy Blog
• [New] Buyers remain interested, but they are taking more time on diligence, valuation and evaluating regulatory risk - including shifts in US policy related to drug pricing - and they are being more surgical about which assets justify a premium. Financier Worldwide
• [New] Antimicrobial resistance is a significant global health problem, with deaths from drug-resistant infections expected to exceed cancer by 2050. Chemistry World
• Pharmaceutical sponsors are becoming more selective in vendor qualification, prioritizing manufacturers with strong compliance track records and global regulatory approvals to minimize the risk of supply disruption. Persistence Market Research
• Fastest-Growing Service Type: Integrated CDMO services are expected to register a CAGR of around 9.1% from 2026 to 2033, owing to pharmaceutical companies consolidating vendors to accelerate development-to-commercialization timelines. Persistence Market Research
• Leading Service Type: Drug substance manufacturing is expected to account for roughly 44% of revenue share in 2026, driven by increasing outsourcing of biologics and complex-molecule production, which require specialized infrastructure. Persistence Market Research
• The Indian Pharmaceutical industry is projected to reach USD 130 billion by 2030 from USD 60 billion in 2026, showing rising future demand of precision fermentation technology. Polaris
• The use of artificial intelligence in drug R&D will allow for quicker identification of targets, selection of candidates, and design of clinical trials. tradingkey.com
• A share of nearly 63.2% is expected to be held by the U.S. in 2026, attributed to increasing research in DNA nanorobots, smart drug delivery systems, and AI-integrated nanomedical devices. Persistence Market Research
• Some 12% of Americans are taking a GLP-1 drug, helping convince millions of users and the many people who have watched their transformation that the key to health, beauty and longevity might come in a syringe. Bloomberg

Last updated: 21 July 2026